Moroccan Sothema to produce Chinese vaccine Sinopharm

Sinopharm’s signage can be seen at the China International Trade in Services Fair (CIFTIS) 2020, following the COVID-19 outbreak, in Beijing, China on September 5, 2020. REUTERS / Tingshu Wang // File Photo

RABAT, July 5 (Reuters) – Moroccan pharmaceutical company Sothema (SOT.CS) will soon start producing 5 million doses per month of the Chinese COVID-19 vaccine Sinopharm (1099.HK) in this South African country. North, state news agency MAP reported on Monday.

The announcement was made during a ceremony chaired by King Mohammed VI during which the Moroccan government, Sinopharm and Sothema, whose official name is Société Thérapeutique Marocaine, also signed agreements to produce the vaccine in Morocco, which has about 36 million inhabitants.

At the same event, the Moroccan government also signed an agreement with Swedish Recipharm (RCPHF.PK) to set up a factory in Morocco to produce other key vaccines.

Morocco, which launched a COVID-19 vaccination campaign in January, has vaccinated more people against the virus than other African countries. He had administered 19.23 million doses of the Sinopharm and AstraZeneca (AZN.L) vaccines as of July 5.

The country has so far received 20.4 million doses and plans to vaccinate anyone over the age of 17. Morocco has recorded 534,550 COVID-19 infections and 9,319 deaths from the virus.

Reporting by Ahmed Eljechtimi Editing by Paul Simao and Jonathan Oatis

Our standards: Thomson Reuters Trust Principles.

Source link

Previous MSF calls on Italy to release the seized rescue vessel | Migration news
Next Mets deserve pitcher like Jose Berrios by MLB trade deadline